News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
280,475 Results
Type
Article (14821)
Company Profile (299)
Press Release (265350)
Multimedia
Podcasts (73)
Webinars (11)
Section
Business (79814)
Career Advice (159)
Deals (13321)
Drug Delivery (38)
Drug Development (50675)
Employer Resources (31)
FDA (5829)
Job Trends (5168)
News (145035)
Policy (10068)
Tag
Academia (921)
Accelerated approval (18)
Adcomms (14)
Allergies (79)
Alliances (21782)
ALS (122)
Alzheimer's disease (1019)
Antibody-drug conjugate (ADC) (220)
Approvals (6010)
Artificial intelligence (242)
Autoimmune disease (98)
Automation (9)
Bankruptcy (105)
Best Places to Work (4564)
BIOSECURE Act (6)
Biosimilars (98)
Biotechnology (230)
Bladder cancer (95)
Brain cancer (43)
Breast cancer (324)
Cancer (2981)
Cardiovascular disease (228)
Career advice (145)
Career pathing (6)
CAR-T (211)
CDC (5)
Cell therapy (543)
Cervical cancer (14)
Clinical research (43464)
Collaboration (1057)
Company closure (2)
Compensation (552)
Complete response letters (36)
COVID-19 (1094)
CRISPR (81)
C-suite (500)
Cystic fibrosis (108)
Data (4139)
Denatured (13)
Depression (82)
Diabetes (247)
Diagnostics (1372)
Digital health (9)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (177)
Drug pricing (43)
Drug shortages (3)
Duchenne muscular dystrophy (204)
Earnings (31547)
Editorial (23)
Employer branding (4)
Employer resources (29)
Events (51456)
Executive appointments (610)
FDA (7462)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (6)
Frontotemporal dementia (21)
Funding (934)
Gene editing (169)
Generative AI (19)
Gene therapy (465)
GLP-1 (489)
Government (1140)
Grass and pollen (3)
Guidances (162)
Healthcare (6607)
HIV (16)
Huntington's disease (40)
IgA nephropathy (73)
Immunology and inflammation (180)
Immuno-oncology (28)
Indications (51)
Infectious disease (1195)
Inflammatory bowel disease (151)
Inflation Reduction Act (10)
Influenza (36)
Intellectual property (154)
Interviews (18)
IPO (7333)
IRA (12)
Job creations (868)
Job search strategy (129)
Kidney cancer (9)
Labor market (22)
Layoffs (242)
Leadership (9)
Legal (1400)
Liver cancer (40)
Longevity (9)
Lung cancer (408)
Lymphoma (241)
Machine learning (22)
Management (7)
Manufacturing (347)
MASH (128)
Medical device (2662)
Medtech (2669)
Mergers & acquisitions (6572)
Metabolic disorders (692)
Multiple sclerosis (94)
NASH (13)
Neurodegenerative disease (211)
Neuropsychiatric disorders (65)
Neuroscience (1882)
NextGen: Class of 2026 (2033)
Non-profit (865)
Now hiring (28)
Obesity (311)
Opinion (122)
Ovarian cancer (124)
Pain (91)
Pancreatic cancer (149)
Parkinson's disease (217)
Partnered (12)
Patents (282)
Patient recruitment (298)
Peanut (43)
People (26539)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase I (15397)
Phase II (20191)
Phase III (12767)
Pipeline (2747)
Policy (86)
Postmarket research (853)
Preclinical (6525)
Press Release (30)
Prostate cancer (138)
Psychedelics (48)
Radiopharmaceuticals (232)
Rare diseases (586)
Real estate (1447)
Recruiting (12)
Regulatory (9735)
Reports (19)
Research institute (968)
Resumes & cover letters (18)
Rett syndrome (22)
RNA editing (17)
RSV (16)
Schizophrenia (119)
Series A (174)
Series B (126)
Service/supplier (1)
Sickle cell disease (75)
Special edition (18)
Spinal muscular atrophy (118)
Sponsored (15)
Startups (2002)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (17)
The Weekly (59)
Vaccines (321)
Venture capital (60)
Weight loss (166)
Women's health (23)
Worklife (2)
Date
Today (152)
Last 7 days (436)
Last 30 days (1192)
Last 365 days (18175)
2026 (446)
2025 (18097)
2024 (20547)
2023 (22419)
2022 (26827)
2021 (27809)
2020 (23366)
2019 (16227)
2018 (11741)
2017 (13747)
2016 (11841)
2015 (14350)
2014 (10400)
2013 (7493)
2012 (7552)
2011 (7620)
2010 (7438)
Location
Africa (153)
Alabama (63)
Alaska (2)
Arizona (67)
Arkansas (5)
Asia (18167)
Australia (3087)
California (6784)
Canada (1783)
China (724)
Colorado (233)
Connecticut (240)
Delaware (226)
Europe (38982)
Florida (854)
Georgia (203)
Hawaii (2)
Idaho (17)
Illinois (375)
India (31)
Indiana (153)
Iowa (8)
Japan (207)
Kansas (79)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (714)
Massachusetts (5382)
Michigan (104)
Minnesota (239)
Mississippi (3)
Missouri (31)
Montana (16)
Nebraska (5)
Nevada (30)
New Hampshire (18)
New Jersey (1586)
New Mexico (12)
New York (1693)
North Carolina (799)
North Dakota (6)
Northern California (3302)
Ohio (174)
Oklahoma (11)
Oregon (24)
Pennsylvania (1225)
Puerto Rico (8)
Rhode Island (25)
South America (211)
South Carolina (9)
Southern California (2684)
Tennessee (38)
Texas (875)
United States (22432)
Utah (92)
Virginia (131)
Washington D.C. (36)
Washington State (564)
West Virginia (1)
Wisconsin (39)
280,475 Results for "nimbus therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug
Eli Lilly kicked off a pivotal 2026 campaign with a multi-year collaboration with current partner Nimbus Therapeutics worth a potential $1.3 billion for a preclinical obesity therapeutic. The deal follows a 2022 partnership struck by the companies to target the AMPK protein in cardiometabolic diseases.
January 6, 2026
·
2 min read
·
Heather McKenzie
Press Releases
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment
January 6, 2026
·
2 min read
Press Releases
Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
December 22, 2025
·
3 min read
Immunology and inflammation
Takeda’s $4B Nimbus Bet Pays Off With ‘Best-in-Class’ Phase III Plaque Psoriasis Data
With zasocitinib, Takeda is looking to challenge Bristol Myers Squibb’s kinase inhibitor Sotyktu, for which the Japanese pharma is running a head-to-head study in plaque psoriasis. Takeda expects to file for zasocitinib’s FDA approval next year.
December 19, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Nimbus Therapeutics Achieves Research Milestone in Collaboration with Lilly
February 25, 2025
·
2 min read
Press Releases
Nimbus Therapeutics Appoints Abbas Kazimi as Chief Executive Officer
March 10, 2025
·
3 min read
Business
Nimbus Therapeutics Appoints Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, Oncology
Nimbus Therapeutics today announced the appointment of Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, Oncology.
May 7, 2024
·
3 min read
Press Releases
Nimbus Therapeutics Announces Clinical Progress in Oncology Therapeutic Pipeline and Provides Business Updates
January 9, 2025
·
4 min read
Business
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
Nimbus Therapeutics, LLC today announced that Katharine Knobil, M.D., has been appointed to the Company’s Board of Directors.
March 12, 2024
·
3 min read
Press Releases
Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
April 28, 2025
·
4 min read
1 of 28,048
Next
